Progressive renal and cardiovascular disease: Optimal treatment strategies

Kidney International

Volumn 62, Issue 4, 2002, Pages 1482-1492

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

Author keywords

Cardiovascular risk; Hypertension; Proteinuria

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; PROTEIN;

ADULT; ALBUMIN BLOOD LEVEL; ANAMNESIS; ARTERIOLE; BLOOD LEVEL; BLOOD PRESSURE; CARBOHYDRATE ANALYSIS; CARDIOMEGALY; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CASE REPORT; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; HEART RATE; HEART RHYTHM; HEPATOSPLENOMEGALY; HUMAN; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; LUNG EXAMINATION; MALE; MOTOR PERFORMANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPHTHALMOSCOPY; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; REVIEW; TENDON REFLEX; TIME; TREATMENT INDICATION;

EID: 0036379551     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00591.x     Document Type: Review

References (50)

1. UK PROSPECTIVE DIABETES STUDY GROUP: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. VACCARO O, RUTH KJ, STAMLER J: Relationship of postload plasma glucose to mortality with 19-yr follow-up. Comparison of one versus two plasma glucose measurements in the Chicago Peoples Gas Company Study. Diabetes Care 15:1328-1334, 1992
3. THE NATIONAL HIGH BLOOD PRESSURE EDUCATOR PROGRAM WORKING GROUP: National High Blood Pressure Program. Working Group Report on Hypertension in Diabetics. Hypertension 23:145-158, 1994
4. NAVAR LG, BURKE TJ, ROBINSON RR, CLAPP JR: Distal tubular feedback in the autoregulation of single nephron glomerular filtration rate. J Clin Invest 53:516-525, 1974
5. WALKER M III, HARRISON-BERNARD LM, COOK AK, NAVAR LG: Dynamic interaction between myogenic and TGF mechanisms in afferent arteriolar blood flow autoregulation. Am J Physiol 279:F858-F865, 2000
6. JUST A, EHMKE HTL, KIRCHHEIM HR: Dynamic characteristics and underlying mechanisms of renal blood flow autoregulation in the conscious dog. Am J Physiol 280:F1062-F1071, 2001
7. SORENSEN CM, LEYSSAC PP, SKOTT O, HOLSTEIN-RATHLOU NH: Role of the renin-angiotensin system in regulation and autoregulation of renal blood flow. Am J Physiol 279:R1017-R1024, 2000
8. KOMERS R, LINDSLEY JN, OYAMA TT: Role of neuronal nitric oxide synthase (NOS1) in the pathogenesis of renal hemodynamic changes in diabetes. Am J Physiol 279:F573-583, 2000
9. WEIR MR, DZAU VJ: The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens 12:205S-213S, 1999
10. ANDERSON S, MEYER TW, RENNKE HG, BRENNER BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76:612-619, 1985
11. KLAHR S, LEVEY S, LEVEY AS, BECK GJ: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
12. WEIR MR, DWORKIN LD: Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy? Am J Kidney Dis 32:1-22, 1998
13. PARVING HH, HOVIND P, ROSSING K, ANDERSEN S: Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515-522, 2001
14. KASISKE BL, KALIL RS, MA JZ: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138, 1993
15. PETERSON JC, ADLER S, BURKART JM: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
16. BAKRIS GL: Maximizing cardio-renal benefits: Achieving blood pressure goals. J Clin Hypertens 1:141-148, 1999
17. JAFAR TH, SCHMID CH, LANDA M: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
18. THE GISEN GROUP: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863, 1997
19. JAFAR TH, STARK PC, SCHMID CH: Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 60:1131-1140, 2001
20. EL NAHAS AM, MASTERS-THOMAS A, BRADY SA: Selective effect of low protein diets in chronic renal diseases. Br Med J (Clin Res Ed) 289:1337-1341, 1984
21. APPERLOO AJ, DE ZEEUW D, DE JONG PE: Short-term antiproteinuric response to antihypertensive therapy predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45(Suppl):S174-S178, 1994
22. ROSSING P, HOMMEL E, SMIDT UM, PARVING HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
23. MOGENSEN CE, KEANE WF, BENNETT PH: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
24. MOGENSEN CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360, 1984
25. KEANE WF, EKNOYAN G: Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33:1004-1010, 1999
26. REMUZZI G, BERTANI T: Pathophysiology of progressive nephropathies. N Engl J Med 339:1448-1456, 1998
27. LEWIS EJ, HUNSICKER LG, BAIN RP, ROHDE RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
28. LEBOVITZ HE, WIEGMANN TB: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45(Suppl):S150-S155, 1994
29. BAKRIS GL, COPLEY JB, VICKNAIR N, et al: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
30. NIELSEN FS, ROSSING P, GALL MA, et al: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46:1182-1188, 1997
31. FOGARI R, ZOPPI A, CORRADI L, et al: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 13:47-53, 1999
32. ESTACIO RO, JEFFERS BW, GIFFORD N, SCHRIER RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2):B54-B64, 2000
33. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al, for The Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
34. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes and mortality in patients with type 2 diabetes and nephropathy: Results of the reduction of end points in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. N Engl J Med 345:861-869, 2001
35. VIBERTI G, MOGENSEN CE, GROOP LC, PAULS JF: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 271:275-279, 1994
36. RAVID M, LANG R, RACHMANI R, LISHNER M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 156:286-289, 1996
37. YUSUF S, SLEIGHT P, POGUE J, et al: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
38. PARVING HH, LEHNERT H, BROCHNER-MORTENSON J, et al, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
39. WEIR MR, WEBER MA, NEUTEL JM, et al: Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: A clinical experience trial. ACTION Study Investigators. Am J Hypertens 14:567-572, 2001
40. RUSSO D, PISANI A, BALLETTA MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33:851-856, 1999
41. LEVEY AS, BETA JA, CORONADO BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
42. NATIONAL INSTITUTES OF HEALTH: US Renal Data System: USRDS 1999 Annual Data Report. Bethesda, MD, National Institute of Diabetes and Digestive Kidney Diseases, 1999
43. nd ed), Bethesda, MD, National Institutes of Health, 1995, pp 349-400
44. SLATAPER R, VICKNAIR N, SADLER R, BAKRIS GL: ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, insulin-dependent diabetic subjects. J Diabetes Complications 8:2-6, 1994
45. BAKRIS GL, WEIR MR, DEQUATTRO V, MCMAHON FG: Effects of ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283-1289, 1998
46. HEEG JE, DE JONG PE, VAN DER HEM GK, DE ZEEUW D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
47. BAKRIS GL, SMITH A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125:201-204, 1996
48. WEIR MR, CHRYSANT SG, MCCARRON DA, et al: Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 31:1088-1096, 1998
49. THE SOLVD INVESTIGATORS: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:685-691, 1992
50. COHN JN, TOGNONI G: (RALES Trial): A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001